Two commercially available enzyme immunoassays and one assembled in house were used to measure immunoglobulin M (IgM) antibody to cytomegalovirus (CMV) in a total of 220 serum specimens from 104 renal transplant recipients. All assays included a step in which interfering IgG antibody was removed or complexed. Concordance of results between pairs of assays ranged from 84 to 96%. All sera from patients with recent seroconversion (primary CMV infection) had measurable anti-CMV IgM. Among those already seropositive to CMV when transplanted, 26 to 55% had IgM antibody posttransplant, depending on the assay. This was observed regardless of the CMV serologic status of the kidney donor, indicating that reactivation of endogenous CMV, as well as reinfection, can induce this antibody in transplant recipients. Four cadaver donors known to transmit CMV to eight recipients did not have measurable IgM antibody to CMV.
Detection of immunoglobulin M (IgM) antibody to cytomegalovirus (CMV) has been proposed as a rapid method of diagnosing primary infection with this virus. Studies have shown that IgM antibody to CMV in pregnant women generally signifies recent primary infection, whereas women those with reactivated or recurrent CMV infection seldom have this antibody (7, 13) . However, in organ transplant populations, CMV-specific IgM antibody is observed in some persons with nonprimary CMV infections (11, 12) although the frequency and significance of this remains incompletely defined because of the relatively small numbers of sera tested and reported so far. Among previously CMVseropositive renal transplant recipients, Betts and Schmidt (2) observed that cytolytic IgM antibody to CMV occurred almost exclusively in those with a seropositive kidney donor, suggesting that the antibody response may have reflected reinfection with a donor strain of CMV. Restriction enzyme analysis of viral isolates from pairs of kidney recipients confirms that CMV reinfection does occur when seropositive kidneys are transplanted into seropositive recipients (4) . This has prompted us to survey a large number of renal transplant recipients, with emphasis on determining whether the presence of anti-CMV IgM in previously seropositive patients denotes reinfection with a donor CMV strain. We also examined a few serum samples from donors known to have transmitted CMV infection to their recipients, because a previous report indicated that a substantial number of infective transfusion donors appeared to have IgM antibody to CMV (1) .
Measurement of IgM antibody has been hampered by a variety of technical problems causing interassay variability (7, 14) , including antigen competition by concomitant IgG antibody and false-positive reactions caused by rheumatoid factor (RF). One solution to these problems is to remove IgG antibody in the serum specimen by absorption or binding methods (8) . Such a strategy is incorporated into each of the three enzyme-linked immunosorbent assays (ELISAs) used in this study. The first assay kit (Cytomegelisa-M; MA BioProducts, Walkersville, Md.), has recently been licensed * Corresponding author.
for clinical diagnostic use, and its performance has been examined and compared with radioimmunoassay in several studies (3, 5, 13 
RESULTS
Concordance of ELISA results. Sera testing positive for anti-CMV IgM had an average (standard deviation) specific absorbance of 1.175 (0.587), 0.494 (0.241), and 0.683 (0.484) for the MA, Behring, and in-house assay, respectively. With 105 serum samples tested using both the commercial assays, there was an 85% concordance of results when the positive cutoff criteria specified by the manufacturer were used in each case (Table 1) . We chose a positive cutoff of 0.2 specific absorbance units for our in-house assay. This gave the best correlation with the MA assay and was also well above values obtained with CMV-seronegative sera; 30 of these serum samples had an average signal of 0.009 absorbance units, with a range of -0.002 to 0.026. Using a positive cutoff of 0.1 on our assay would have given a positive result with 18 additional serum samples, none of which represented primary infection; 4 were associated with known concurrent viruria, an additional 2 were from patients who shed CMV some time in the first 3 months posttransplant, and 6 each were pre-and posttransplant specimens on asymptomatic seropositive recipients.
Most of the discordant results were encountered with serum samples from CMV-seropositive recipients, which registered a positive result with the MA and in-house assays but negative on the Behring assay. Two of three serum samples, IgM-negative on the MA assay but positive on the Behring assay, were negative on repeat testing with the latter assay; these samples were from seronegative patients who did not seroconvert after several further months of follow-up. One serum sample from a patient with primary infection was initially negative with the Behring kit because of high reactivity with uninfected cell antigen; on repeat testing, reactivity with control antigen decreased enough to give a positive result. With 102 serum samples tested with the MA kit and the in-house assay, there was a 96% concordance of results ( Table 2 ). The only discordant results involved two pretransplant and two posttransplant serum samples from seropositive recipients, which were positive only on the MA assay. One of these four serum samples involved a patient reinfected with a donor strain of CMV (signal 0.112 with in-house assay); with the other three Table 4 ). The adequacy of the RFremoval steps used in these assays has been previously documented (8) .
IgM antibody in recipient groups. Prevalence of IgM antibody in seropositive and seronegative recipients is shown in Table 4 . Seronegative recipients were negative for IgM antibody at time of transplant and at follow-up, unless they acquired primary infection, in which case 100% developed IgM antibody. Primary infections were defined by seroconversion (negative to positive by IgG ELISA [6] ), and all were confirmed by detection of viruria or viremia.
Pretransplant serum samples from seropositive recipients had a 5 to 25% prevalence of IgM antibody, depending on the assay. Three of these samples were from patients who were known to have had a primary CMV infection (seroconversion) within the past year; the other serum samples testing positive did not appear to be associated with active CMV infection. The one specimen in this study known to come from a viruric pretransplant patient tested negative on all three assays.
Posttransplant serum samples on seropositive recipients showed that 26 to 55% (depending on the assay) had IgM antibody. This occurred whether the organ donor was seropositive or seronegative. Seropositive recipients of seropositive kidneys had anti-CMV IgM more frequently than recipients of seronegative kidneys, but the difference was not statistically significant and could have been related to the prevalence of viral shedding in the two groups. Taking only patients known to be shedding virus at the time of specimen collection, 3 of 5 recipients of a seronegative kidney, and 7 of 12 recipients of a seropositive kidney had CMV IgM by the in-house assay. Posttransplant specimens were available on three recipients with molecular epidemiologic evidence of reinfection (4). One was highly reactive in all three assays, one was positive on two assays (MA and in house), and the third was positive only on the MA assay. The intensity of positive signals tended to be highest among those with primary infection, intermediate among seropositive recipients of seropositive kidneys, and lowest among seropositive recipients of seronegative kidneys, but there was a considerable overlap among these groups. For example, with our in-house assay, the average (standard deviation) positive signal was 0.836 (0.407), 0.744 (0.527), and 0.541 (0.450) absorbance units for the three patient groups, respectively.
IgM antibody in donor sera. Serum samples from four seropositive kidney donors who transmitted CMV to eight recipients (confirmed by restriction enzyme analyses ) were assayed for IgM with the in-house ELISA; none was positive. One was tested with all three ELISAs and was negative on all of them.
DISCUSSION
Using three ELISAs, we found specific IgM antibody to CMV in all instances of posttransplant primary CMV infection where IgG seroconversion had occurred. We also found the antibody in a some CMV IgG-seropositive recipients at time of transplant and considerably more of them at posttransplant follow-up, regardless of the serologic status of the donor. Only about half of reactivation infections, as defined by viral shedding in a seropositive recipient, are associated with measurable IgM antibody. This is consistent with previously published data (9, 11) . We also did not find IgM antibody to CMV in four cadaver donors who transmitted CMV to eight recipients. Thus, lack of this antibody in prospective donors does not exclude CMV infectivity and is not an adequate donor screening procedure, although a previous study showed that 12 of 28 patients developing posttransfusion CMV infection had received blood containing CMV IgM (1).
Published experience with CMV-specific IgM assays, as well as our own experience in assembling an ELISA, indicate the need for a strategy to eliminate false-positive reactions due to RF and to reduce signal suppression due to IgG antibody competition for the same antigen. We have found the methods used in the present assays for removal of reactive IgG to be attractive because they allow the use of an assay protocol closely analogous to that used for measuring IgG antibody, a much more frequently used test. Use of sheep anti-human-IgG serum, as in the Behring assay and our in-house assay, is especially convenient since this eliminates a time-consuming centrifugation step needed with staphylococcal absorption in the MA assay.
In comparing the two commercial assays, both did well in identifying IgM in those with recent primary infection with seroconversion, but the Behring assay, which appears to be less sensitive, identified fewer of those with reactivation or reinfection or both. Our in-house assay, which uses a different antigen from the Behring kit but is otherwise similar, gave many more positive results with the same sera, and was closely concordant with the MA kit. Deciding the proper cutoff level for a positive result is problematic, since there is no generally recognized reference assay, and there is a tendency for borderline results with sera from seropositive recipients, in whom evidence of active infection is often inconclusive. A recent study (5) suggested that the correlation of the MA assay with radioimmunoassay was best when the ELISA cutoffwas increased from 0.3 absorbance unit, as suggested by the manufacturer, to 0.6 absorbance unit, indicating that the MA assay may be overly sensitive. This could account for some of the pretransplant sera that tested positive on the MA assay, in recipients who did not appear to have active CMV infection.
